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A B S T R A C T
Peroxisome proliferator activated receptor-g (PPARG) and lipoprotein lipase (LPL) play important role in lipid ho-
meostasis, insulin resistance and adipogenesis, and their gene variability could be considered as predictive genetic mar-
kers for metabolic syndrome (MetSy). The aim of the study was to estimate possible associations of PPARG (Pro12Ala)
and LPL PvuII (+/–) polymorphisms with MetSy and its traits. Study included 527 subjects. According to the modified
National Cholesterol Education Program Adult Treatment Panel III definitions, subjects were classified into the meta-
bolic syndrome group and control group. Genotyping was performed using polymerase chain reaction-restriction frag-
ment length polymorphism methods. In the total sample, LPL variants were associated with waist circumference (c2=
7.263, d.f.=2, p=0.026) and with BMI (c2=6.549, d.f.=2, p=0.038), where PvuII (+/+) genotype carriers had the highest
risk for increased waist circumference (specific PvuII (+/+) vs. others analysis c2=7.033, p=0.008) and increased BMI
(specific Pvu II(+/+) vs. others analysis c2=5.154, p=0.023). LPL gene variants were also associated with HDL-C levels
(c2=6.901, d.f.=2, p=0.032), where PvuII (–/–) genotype carriers had higher HDL-C values in comparison to others (spe-
cific Pvu (+/+) vs. others analysis c2=6.504, p=0.011). Furthermore, PvuII (–) allele carriers had significantly lower
glucose (allele based analysis Add Value=–0.0878, c2=5.878, d.f.=1, p=0.015). Significant interaction was detected be-
tween PPARG and LPL that affected HDL-C levels in male population (c2=11.790, d.f.=1, p=0.0006) in the manner that
Ala/PvuII(+) contributed to the lowest HDL-C values (Specific Ala/ Pvu(+) vs. others analysis was c2=11.750, p=
0.0006). According to obtained results LPL and PPARG gene variants could be susceptibility factors of obesity and lipid
status, contributing to development of MetSy, particularly in males. Because of antiatherogenic function of HDL-C, the
identification of genetic variants associated with HDL-C can provide useful information related to genotype-phenotype
relationships. Since the interplay between PPARG and LPL gene and gender seems to be significant it could point to the
personalized behavioural recommendations for prevention of metabolic and cardiovascular diseases.
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Introduction
Metabolic syndrome (MetSy) is a rising global public
health problem because of its role in increasing the risk
of cardiovascular disease and type 2 diabetes mellitus
(T2DM). It is a cluster of modifiable risk factors includ-
ing hypertension, abdominal obesity, dyslipidemia and
insulin resistance, and of nonmodifiable risk factors,
such as age, sex and genetic background1. The underly-
ing determinants of individual susceptibility to MetSy
form a complex network of interactions between genetic
and environmental risk factors, as a consequence of their
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multi-factorial nature. Although considerable efforts ha-
ve been made toward controlling all these risk factors,
progress seems to be most prominent in the field of
dyslipidemia. Serum lipid levels, including high-density
lipoprotein cholesterol (HDL-C) and triglycerides (TGs),
two components of the MetSy, are highly heritable, with
estimates consistently over 50%2,3. While the importance
of genetic factors to the development of MetSy has been
widely recognized, the contribution of genes has not yet
been fully clarified. Many association studies have been
conducted with inconsistent results4,5.
Peroxisome proliferator activated receptor-g (PPARG)
and lipoprotein lipase (LPL) are the two important pro-
teins that play a key role in lipid homeostasis, insulin re-
sistance and adipogenesis, and their gene variability
could be considered as predictive genetic markers for
MetSy.
PPARs (PPAR-a, PPAR-d and PPAR-g) are transcrip-
tion factors that belong to the nuclear hormone receptor
superfamily that regulate various genes involved in lipid
and glucose metabolism, fatty acid transport, adipocyte
differentiation, carcinogenesis, and inflammation6. The
PPARG gene is located on chromosome 3p25 (OMIM
number 601487). Because of alternative mRNA splicing,
two protein isoforms occur: PPARG1 and PPARG2. Whi-
le PPARG1 is found ubiquitously in the body, PPARG2 is
largely found in adipose tissue and the large intestine.
Among several variants in the PPARG gene, the Pro12Ala
variant (rs1801282) has been most extensively examined
in epidemiologic studies. The frequency of the 12Ala al-
lele has been found to range from 2 to 18% in healthy
people7. The substitution from proline to alanine at co-
don 12 has been found to modulate transcriptional activ-
ity. Ala variant has been shown to have a reduced affinity
for the response element in target genes, which leads to
the less efficient stimulation of PPARG target genes8.
PPARG function appears to be a key factor in mediating
conditions such as dyslipidemia, obesity, and insulin re-
sistance9,10, and has also been implicated in the develop-
ment of cardiovascular diseases11.
LPL belongs among different PPARG target genes
and play the major role in the metabolism and transport
of lipids. It is the enzyme responsible for the hydrolysis
of core TGs. LPL has many physiological functions by
which it regulates the supply of fatty acids to various tis-
sues. Its interaction with lipoproteins facilitate lipopro-
tein particle uptake in the vessel wall. LPL also takes
part in the kinetics of the majority of plasma lipoprotein
particles, supporting the exchange of lipids between lipo-
proteins. To enhance lipoprotein uptake LPL molecules
can even serve as ligands for lipoprotein receptors. In ad-
ipose tissue during adipocyte differentiation insulin in-
crease LPL gene transcription enhancing considerably
LPL activity12. Glucose also increases adipose tissue LPL
activity.
The LPL gene has been mapped to human chromo-
some 8p22. Several LPL mutation loci have been de-
tected and investigated for their associations with plas-
ma lipid level and the development of cardiovascular
diseases13. Polymorphism LPL Pvu II (–/+) (rs285) is
caused by the absence (–) or presence (+) of a C>T tran-
sition at position 497 in intron 6, and may interfere with
correct splicing of mRNA, diminishing the enzyme activ-
ity.
Results of association studies of PPARG and LPL
gene polymorphisms with MetSy and its traits have been
inconsistent.
Assuming a modest role of single polymorphisms as
markers of complex traits and diseases, the study of vari-
ant gene combinations could provide complementary in-
formation that could be clinically important. Besides, the
influence of gene variants on phenotype expression
seems to be population specific because of possible varia-
tions in genetic and environmental factors and interpo-
pulation differences in genetic background14. Here we
consider the relations between the PPARG and LPL gene
polymorphisms and MetSy traits in Croatian population.
We also tested if the modulation of clinical and biochemi-
cal parameters of MetSy by interplay between PPARG
and LPL genes is gender specific.
Subjects and Methods
Subjects
The required sample size was calculated for the tar-
geted power of 80%, and the confidence level of 95%. A
Chi-square (c2) test was used for testing of the first hy-
pothesis: difference in prevalence of one (or more) meta-
bolic syndrome parameters between subjects with differ-
ent LPL variants PvuII (–/–), (–/+) and (+/+). The smal-
lest effect size to be detected by Chi-square test was set
at 0.15. Under these assumptions, the required final
sample size was estimated at n=429. Initially required
sample size was increased by 10% and was estimated at n
=472 subjects. Finally a total of 527 subjects (343 female,
184 male) of Croatian origin, participated in the study.
Participants were recruited among outpatients admitted
to the University Hospital Center Zagreb, and among
hospital staff and other Zagreb citizens, appointed for
routine check up. MetSy was defined using the criteria
established in the third report of the National Choles-
terol Education Program Expert Panel on Detection,
Evaluation, and Treatment in Adults15. An individual
with a combination of any three or more of the following
risk factors was classified as having MetSy: waist circum-
ference, male >102 cm, female >88 cm; TG ³1.7 mmol/L;
HDL-C <1.0 in men and <1.3 mmol/L in women; systolic
blood pressure (SBP) or diastolic blood pressure (DBP)
³130/85 mmHg, or use of anti-hypertensive medications;
and fasting blood glucose ³6.1 mmol/L or use of antidia-
betic medication with the age of diagnosis of T2DM ³40
years. In the case of participants’ use of medications, for-
mulas were applied that were based on previous re-
search16 which involved corrections of a participant’s
medicated traits according to the mean values of many
summarized clinical trials. TG and HDL-C for the sub-
jects treated with antihyperlipidemics were corrected to
new values based on the following formula: TG/(1–15.2/
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100), HDL-C/(1+6.1/100). The SBP and DBP for subjects
using antihypertensives were corrected to new values ac-
cording to the formula: SBP+14.8 and DBP+10.5 (mm
Hg). Data were collected from each participant on clini-
cal variables including age, height, weight, and waist cir-
cumference. Body mass index (BMI) was calculated as
weight (kg) / height (m2). Blood samples for biochemical
analyses (total cholesterol, TG, LDL-C, HDL-C, and glu-
cose) were collected after overnight fasting and analyzed
by using routine laboratory methods. All participants
signed informed consent forms, and the study protocol
was approved by Ethics Committee of the University
Hospital Center Zagreb.
Genotyping procedures
Genomic DNA was extracted from blood leukocytes
and genotyping of PPARG (Pro12Ala) and LPL PvuII
(–/+) was performed according to previously published
methods17,18.
Statistical analysis
The required sample size was calculated in 11th PASS
Hintze, J. (2011), NCSS, LLC. Kaysville, Utah, USA.
www.ncss.com. The statistical analysis was performed
using SPSS for Windows version 13.0 (SPSS Inc., Chi-
cago, IL, USA). Study subjects were described using
means and standard deviations for interval measures
and frequencies and percentages for categorical vari-
ables. For testing the normality of data distribution,
Kolmogorov-Smirnov goodness of fit test was used (with
p>0.05 considered as a non-significant departure from
normality). Chi-square tests were used to compare differ-
ent categorical variables, including genotypes between
cases and controls and between males and females. To
compare different continuous variables between cases
and controls and between males and females we used
Mann-Whitney or t-tests for independent samples where
variables were non-parametric and parametric, respec-
tively.
The association of PPARG and LPL gene variants
with the MetSy components (the levels of TG, glucose,
HDL-C, blood pressure and waist circumference) was
tested using program UNPHASED ver. 3.0.10. We ana-
lyzed associations of MetSy components with alleles, ge-
notypes, specific genotypes (estimating the odds ratios
and additive values of individual genotype vs. others) and
cis gene-gene interactions. The sequential Bonferroni ad-
justments were applied to correct for the effect of multi-
ple tests using SAS Release 8.02 (SAS Institute, 1999).
The equivalence of the genotype distribution to the Har-
dy-Weinberg equilibrium was tested using the online
software (http://ihg2.helmholtz-muenchen.de/cgi-bin/hw/
hwa1.pl).
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TABLE 1
CLINICAL FEATURES OF STUDY PARTICIPANTS
Patients
Mean±SD
Controls
Mean±SD
p
Age (yrs) 52.13±10.68 51.62±10.40 0.188
Gender (N of male participants/All) 98/263 85/264 0.222
BMI (kg/m2) 32.20±4.75 24.57±3.36 <0.001
Waist circumference (cm) 107.29±11.24 86.25±11.74 <0.001
TG (mmol/L) 2.59±2.17 1.22±0.74 <0.001
Cholesterol (mmol/L) 5.76±1.27 5.52±1.02 0.039
HDL-C (mmol/L) 1.34±0.32 1.69±0.41 <0.001
LDL-C (mmol/L) 3.46±1.31 3.30±0.89 0.242
Glucose (mmol/L) 6.23±2.22 4.98±0.77 <0.001
High Blood pressure (N of subjects with high BP/All) 195/257 53/254 <0.001
Systolic blood pressure 152.4±26.0 124.8±14.24 <0.001
Diastolic blood pressure 94.4±15.87 79.5±8.60 <0.001
Genotype N N
ProPro 198 201
PPARG ProAla 62 60 0.974
AlaAla 3 3
PvuII(–/–) 63 70
LPL PvuII(–/+) 122 134 0.194
PvuII(+/+) 78 60
BMI – body mass index, TG – triglycerides, HDL-C – high-density lipoprotein cholesterol, LDL-C – low-density lipoprotein cholesterol,
BP – blood pressure. Differences between groups were evaluated by t-test, Mann-Whitney test or chi-square test depending on distri-
bution normality.
Results
Description of the sample
Clinical features of study participants are given in Ta-
ble 1. A total of 527 subjects (343 female, 184 male) of
Croatian origin, participated in the study, 263 partici-
pants met criteria for MetSy and 264 were without
MetSy criteria and served as controls. Participants with
MetSy had significantly higher blood pressure, BMI and
waist circumferences and higher levels of TG, total cho-
lesterol and glucose and lower levels of HDL-C compared
to controls. MetSy and control group did not differ signif-
icantly with respect to age and sex. In comparison to
males, females were younger, had smaller BMI and waist
circumference, higher TG and glucose levels and had
lower HDL-C. Males had significantly more often high
blood pressure. No differences in genotype distribution
according to gender were detected (Table 2).
Genetic analysis
Frequencies of the PPARG (Pro12Ala) variants Pro-
Pro, ProAla, AlaAla were 399 (75.7%), 122 (23.2%) and 6
(1.1%), respectively. Frequencies of the LPL variants
PvuII (–/–), (–/+) and (+/+) were 133 (25.2%), 256
(48.6%) and 138 (26.2%), respectively. No departure from
the Hardy-Weinberg equilibrium (PPARG controls p=
0.5267 and cases p=0.4446; LPL controls p=0.7873 and
cases p=0.2617) was observed.
Associations of PPARG and LPL gene
variants and MetSy
No differences in PPARG and LPL genotype distribu-
tions between MetSy cases and controls have been found
(Table 2).
Associations of PPARG and LPL gene
variants and MetSy components
No associations of PPARG variants and the compo-
nents of MetSy have been observed (data not shown).
In the total sample, LPL variants were associated
with waist circumference (c2=7.263, d.f.=2, p=0.026)
and with BMI (c2=6.549, d.f.=2, p=0.038), where PvuII
(+/+) genotype carriers had the highest risk for in-
creased waist circumference (specific PvuII (+/+) vs.
others analysis c2=7.033, p=0.008) and increased BMI
(specific Pvu II(+/+) vs. others analysis c2=5.154, p=
0.023). LPL gene variants were also associated with
HDL-C levels (c2=6.901, d.f.=2, p=0.032), where PvuII
(–/–) genotype carriers had higher HDL-C values in com-
parison to others (specific Pvu (+/+) vs. others analysis
c2=6.504, p=0.011) (Table 3). Furthermore, PvuII (–)
carriers had significantly lower glucose (allele based ana-
lysis Add Value=–0.0878, c2=5.878, d.f.=1, p=0.015; ge-
notype based analysis revealed an association of border-
line statistical significance c2=5.821, d.f.=2, p= 0.054)
(Table 3). These associations remained positive after se-
quential Bonferroni corrections (a was set at 0.05 for ge-
notype and 0.025 for allele based analyses). No associa-
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TABLE 2
CLINICAL AND GENETIC DATA ACCORDING TO GENDER
Males
(N=184)
Mean±SD
Females
(N=343)
Mean±SD
p
Age (yrs) 53.56±12.32 50.98±9.35 0.014
BMI (kg/m2) 29.00±5.28 28.13±5.78 0.042
Waist circumference (cm) 104.23±12.81 94.96±15.87 <0.001
TG (mmol/L) 2.46±2.63 1.67±1.09 <0.001
Cholesterol (mmol/L) 5.63±1.31 5.65±1.08 0.573
faautoHDL-C (mmol/L) 1.37±0.40 1.57±0.40 <0.001
LDL-C (mmol/L) 3.40±1.43 3.37±0.95 0.584
Glucose (mmol/L) 6.01±2.06 5.45±1.63 <0.001
High Blood pressure (N of subjects with high BP/All) 100/180 148/331 0.019
Genotype N N
ProPro 132 267
PPARG ProAla 47 75 0.139
AlaAla 4 2
PvuII(–/–) 46 87
LPL PvuII(–/+) 81 175 0.206
PvuII(+/+) 56 82
BMI – body mass index, TG – triglycerides, HDL-C – high-density lipoprotein cholesterol, LDL-C – low-density lipoprotein cholesterol,
BP – blood pressure. Differences between groups were evaluated by t-test, Mann-Whitney test or chi-square test depending on distri-
bution normality.
tions between the LPL variants and other components of
MetSy were found (data not shown).
Since significant associations were found for the who-
le sample, we conducted further analyses in the two gen-
der-based subgroups. Significant associations were ob-
served between LPL and the components of MetSy in the
male subgroup only (Table 4). LPL variants were associ-
ated with BMI, and waist circumference where PvuII (+)
allele carriers had increased risk for higher BMI (Add
Value=0.0639, c2=9.724, d.f.=1, p=0.002 for allele based
analysis and c2=8.901, d.f.=2, p=0.012 for genotype
based analysis) and waist circumference (Add Value=
0.0202, c2=5.313, d.f.=1, p=0.021 for allele based analy-
sis), although the later did not remain positive after se-
quential Bonferroni corrections (a was set at 0.025 for
genotype and 0.0125 for allele based analyses).
Furthermore, significant gene interaction was de-
tected between PPARG and LPL that affected HDL-C
levels (c2=11.790, d.f.=1, p=0.0006) in the manner that
Ala/PvuII(+) contributed to the lowest HDL-C values
(Specific Ala/ Pvu(+) vs. others analysis was c2=11.750,
p=0.0006). These associations remained positive after
sequential Bonferroni corrections (a was set at 0.0125
and 0.00625, respectively) (Table 5).
However, no associations between the LPL variants
and glucose levels were found when the two gender sub-
groups were analyzed separately (data not shown).
Discussion
The obtained results show independent and interact-
ing effects of the LPL and PPARG polymorphisms on
MetSy traits, as follows:
1. Presence of LPL PvuII (+/+) (low activity) geno-
type predisposes for increased waist circumference and
BMI; showing a stronger effect in males,
2. Presence of LPL PvuII (–/–) (high activity) geno-
type predisposes for increased HDL-C,
3. Presence of LPL PvuII (–) (high activity) allele pro-
tects from elevated glucose level,
4. LPL and PPARG gene interaction confers to HDL-
-C levels, where Ala/Pvu(+) low activity allele combina-
tion predisposes for decreased HDL-C values, observed
in males.
Our results pointed to the pleiotropic role of LPL gene
with the influence on several MetSy traits: waist circum-
ference, BMI, HDL-C and glucose. Previously published
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TABLE 3
ASSOCIATIONS OF LPL PvuII (–/+) GENE VARIANTS AND METABOLIC SYNDROME TRAITS
Feature
LPL
Genotype
N
Marginal
Frequency
Additive value CI a Specific p p
BMI
PvuII(–/–)
PvuII(–/+)
PvuII(+/+)
129
250
138
0.250
0.484
0.267
0
0.022
0.055
0
–0.018 – 0.061
0.011 – 0.099
0.064
0.604
0.023
0.038
Waist
circumference
PvuII(–/–) 112 0.246 0 0 0.303
0.026PvuII(–/+) 217 0.476 0.0004 –0.015 – 0.016 0.120
PvuII(+/+) 127 0.279 0.019 0.002 – 0.036 0.008
Glucose
PvuII(–/–) 125 0.249 0 0 0.024
0.054PvuII(–/+) 248 0.493 0.092 –0.080 – 0.265 0.704
PvuII(+/+) 130 0.258 0.176 0.0002 – 0.352 0.088
HDL-C
PvuII(–/–) 125 0.249 0 0 0.011
0.032PvuII(–/+) 247 0.492 –0.609 –1.127 – (–0.090) 0.226
PvuII(+/+) 130 0.259 –0.708 –1.315 – (–0.102) 0.205
BMI – body mass index, HDL-C – high-density lipoprotein cholesterol, CI – confidence interval
a Specific p – individual vs. others genotypes
TABLE 4
ASSOCIATIONS OF LPL PvuII (–/+) GENE VARIANTS AND METABOLIC SYNDROME TRAITS IN MALES
Feature
LPL
Genotype
N
Marginal
Frequency
Additive
value CI
a Specific p p
BMI
PvuII(–/–)
PvuII(–/+)
PvuII(+/+)
46
81
56
0.251
0.443
0.306
0
0.067
0.119
0
–0.053 – 0.139
0.040 – 0.199
0.015
0.871
0.018
0.012
BMI – body mass index, CI – confidence interval
a Specific p – individual vs. others genotypes
results suggest the existence of interaction between LPL
gene and central obesity19,20, which is in accordance with
our findings. LPL is an important marker for adipocyte
differentiation, and LPL expression increases in parallel
with cellular TG accumulation as preadipocytes differen-
tiate. As both central obesity and serum lipids were
found related with LPL activity, it is reasonable to as-
sume that LPL gene variability contribute to the devel-
opment of some of MetSy traits. Obese patients have a
lower gene expression of factors (including LPL) related
with lipid uptake and processing, in comparison with
healthy lean persons20. This is concordant with our re-
sults showing that low activity LPL genotype predisposes
for increased waist circumference and BMI. Considering
the interplay between LPL, insulin and glucose, and the
association of LPL and insulin resistance, our finding
that LPL PvuII high activity allele protects from ele-
vated glucose level is in agreement with published da-
ta21,22. Although LPL does not act directly on HDL, its ac-
tion on triglyceride-rich lipoproteins has an important
indirect effect on HDL metabolism23. The amount of cho-
lesterol transported in HDL particles is measured as
HDL-C and seems to be under considerable genetic con-
trol with heritability estimates of up to 80%24. However,
the genes identified so far together explain only a small
portion of the HDL-C variance. HDL-C loci discovered
via genome-wide association studies (GWAS) for obesity,
MetSy and multiple cardiovascular-related traits pointed
to the LPL4 and PPARG gene25. Some other literature
data also point to the correlation of LPL with obesity
and/or MetSy traits26.
Frequency of PPARG Ala variant in Croatian popula-
tion is estimated to be 12.7%, which is similar to other
European populations7. While some studies have pro-
vided evidence for the association of the PPARG Ala vari-
ant with increased BMI, others have failed to confirm
this finding. We found that common variants of LPL
PvuII (–/+) and PPARG (Pro12Ala) could modulate some
MetSy traits differentially in men and women. Gender-
-based dimorphism has been reported for several genes
that affect MetSy traits and related diseases27. Possible
explanations for this gender-based dimorphism include:
1. possible interaction of LPL with either sex-linked
genes and/or sexual hormone effects28; 2. the effects of
differentially expressed autosomal genes in males and fe-
males; 3. differential fat distribution patterns between
genders; 4. differential gene-environment and gene-gene
interactions. Gender influences the risk for many com-
mon diseases that affect both men and women, including
atherosclerosis and diabetes and their preceding risk fac-
tors (e.g. hyperlipidemia, insulin resistance, and obe-
sity)29. Although PPARG Pro12Ala variant in this study
showed no influence on MetSy or its traits when tested
separately, its interaction with LPL PvuII (–/+), variants
seems to be relevant at least for HDL-C levels in male
population. In their heritability estimation of sex-specific
effects on human quantitative traits, Pan et al. have con-
firmed significant sex-specific autosomal effects on HDL-
-C28. Considering transcriptional regulation, the activity
of the LPL promoter has been studied extensively. The 5’
regulatory region contains a large number of specific
cis-acting elements, among others the PPAR response el-
ement (PPRE)30. Because the LPL promoter was shown
to be ~ 30% less efficiently transactivated in the presence
of the PPARG Ala allele in a study in vitro, Schneider
group proved that the Pro12Ala substitution may lead to
decreased LPL activity in vivo31. Considering that LPL
activity positively correlates with the plasma concentra-
tion of HDL-C, results of our study are in line with the
Schneider group’s hypothesis: we found a combination of
the low activity alleles PPARGAla/LPL PvuII (+), adding
1.8 times higher risks for lower HDL-C values in males
whereas the risk was not increased for the carriers of ei-
ther of two genotypes when analyzed separately. Because
of antiatherogenic function of HDL, the identification of
genetic variants associated with HDL-C can provide use-
ful information and we believe that our data pointed to
the importance of studying LPL and PPARG interac-
tions.
Study Limitations
This study has some limitations: genetic association
studies require very large cohorts to reach an acceptable
power. Therefore the size of our population might be a
limitation. Another limitation might be that the effects
of environmental factors (e.g., physical activity, diet, and
smoking) and controlling the risk of obesity and MetSy
were not evaluated in this study.
In spite of these limitations, the data obtained con-
firm that LPL gene variability contributes in the modu-
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TABLE 5
EFFECTS OF PPARG ProAla AND LPL PvuII(–/+) GENE INTERACTION ON HDL-C LEVEL IN MALES
Interactions/
feature
Haplo types N
Marginal
Frequency
Additive
value
CI a Specific p p
LPLxPPARG/
HDL-C
PvuII(–)/Pro 135.9 0.414 0 0 0.806
0.0006
PvuII(–)/Ala 19.14 0.058 1.544 0.447 – 2.642 0.173
PvuII(+)/Pro 141.1 0.430 0.185 –0.412 – 0.782 0.844
PvuII(+)/Ala 31.86 0.097 –1.786 –3.558 – (–0.013) 0.0006
HDL-C – high-density lipoprotein cholesterol, CI – confidence interval
a Specific p – individual vs. others genotypes
lation of certain clinical and biochemical parameters of
MetSy. Although further studies are needed to confirm
the gender specificity of LPL and PPARG interaction,
the interplay between genes and gender seems to be sig-
nificant and could point to the personalized behavioural
recommendations for prevention of metabolic and car-
diovascular diseases.
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UTJECAJ POLIMORFIZAMA GENA ZA LIPOPROTEIN LIPAZU I RECEPTORA ZA AKTIVATOR
PROLIFERACIJE PEROKSISOMA-GAMA NA SASTAVNICE METABOLI^KOG SINDROMA
S A @ E T A K
Receptor za aktivator proliferacije peroksisoma tip g (PPARG) i lipoprotein lipaza (LPL) imaju va`nu ulogu u lipid-
noj homeostazi, inzulinskoj rezistenciji i adipogenezi i stoga se njihova genska varijabilnost mo`e smatrati mogu}im
prediktivnim biljegom metaboli~kog sindroma (MetSy). Cilj istra`ivanja bio je ispitati povezanosti izme|u polimor-
fizma PPARG (Pro12Ala) i LPL PvuII (–/+) s MetSy i njegovim sastavnicama. U studiju je bilo uklju~eno 527 ispi-
tanika. Prema kriterijima ameri~kog programa za edukaciju o kolesterolu (National Cholesterol Education Program –
Third Adult Treatment Panel, NCEP-ATP III) ispitanici su podijeljeni u skupinu s metaboli~kim sindromom i kon-
trolnu skupinu. Genotipizacija je provedena metodama temeljenim na polimeraznoj lan~anoj reakciji i analizi duljine
restrikcijskih ulomaka (PCR-RFLP). U ukupnom uzorku LPL varijante su bile povezane s opsegom struka (c2=7.263,
d.f.=2, p=0.026) i s BMI (c2=6.549, d.f.=2, p=0.038), pri ~emu su nosioci genotipa LPL PvuII (+/+) imali najve}i rizik
za pove}ani struk (specifi~ni PvuII (+/+) vs. ostali c2=7.033, p=0.008) i pove}ani BMI (specifi~ni Pvu II(+/+) vs. ostali
c2=5.154, p=0.023). LPL genske varijante su tako|er povezane s razinom HDL-C (c2=6.901, d.f.=2, p=0.032), pri
~emu su nosioci genotipa PvuII (–/–) imali vi{e vrijednosti HDL-C u odnosu na ostale (specifi~ni Pvu (+/+) vs. ostali
c2=6.504, p=0.011). Nosioci alela PvuII (–) su tako|er imali zna~ajno ni`e vrijednosti glukoze (Add Value=–0.0878,
c2=5.878, d.f.=1, p=0.015). Uo~ena je zna~ajna interakcija izme|u PPARG i LPL s utjecajem na razine HDL-C u mu{-
koj populaciji (c2=11.790, d.f.=1, p=0.0006), pri ~emu su nosioci Ala/PvuII(+) imali najni`e vrijednosti HDL-C (spe-
cifi~ni Ala/Pvu(+) vs. ostali c2=11.750, p=0.0006). Na osnovi dobivenih rezultata varijante gena LPL i PPARG bi se
mogle ubrojiti u geneti~ke ~imbenike pove}ane podlo`nosti za razvoj debljine i lipidnog statusa koji doprinose razvoju
MetSy, posebno u mu{koj populaciji. Zbog antiaterogene uloge koju ima HDL-C, identifikacija geneti~kih varijacija
povezanih s HDL-C mo`e rezultirati korisnim podacima u svrhu procjene geneti~kog rizika. U tom smislu dobiveni
podaci podupiru va`nost ispitivanja interakcija gena LPL i PPARG sa svrhom stvaranja personaliziranih preporuka
pona{anja i s kona~nim ciljem prevencije metaboli~kih i kardiovaskularnih bolesti.
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